The blood cancer that became solvable
14 hours ago
- #Multiple myeloma
- #CAR-T therapy
- #Drug discovery
- Multiple myeloma is a painful cancer originating in bone marrow, where abnormal plasma cells proliferate, destroying bone from within.
- Traditional treatments (surgery, radiotherapy, chemotherapy) are blunt tools that offer limited cure potential for advanced or relapsed cases.
- Immunotherapy, particularly CAR-T therapies like Carvykti, represents a transformative approach, offering durable remissions via a single infusion.
- Carvykti targets BCMA, a protein highly expressed on myeloma cells, using genetically modified T cells to seek and destroy cancer.
- Carvykti's development highlights China's growing role in drug discovery, due to faster regulatory processes and clinical trial execution.
- Current myeloma treatment involves brutal induction therapy, stem cell transplant, and maintenance, often leading to relapse and reduced quality of life.
- CAR-T therapies, especially when used earlier in treatment, show superior progression-free survival and potential for cure compared to older methods.
- China's biotech advancement is driven by industrial policy, rapid investigator-initiated trials, and repatriation of scientists, challenging US dominance.
- US regulatory bottlenecks slow early-stage trials, while China's agility in iteration and feedback between clinic and lab accelerates innovation.
- Western companies still lead late-stage development, but the early-stage pipeline is increasingly Chinese, risking future competitive displacement.